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Pneumocystis jirovecii pneumonia (PcP) is a major human immunodeficiency virus (HIV)-
related illness, rising among immunocompromised non-HIV patients and in developing
countries. Presently, the diagnosis requires respiratory specimens obtained through
invasive and costly techniques that are difficult to perform in all patients or implement
in all economic settings. Therefore, the development of a faster, cost-effective, non-
invasive and field-friendly test to diagnose PcP would be a significant advance. In this
study, recombinant synthetic antigens (RSA) of P. jirovecii’s major surface glycoprotein
(Msg) and kexin-like serine protease (Kex1) were produced and purified. These RSA
were applied as antigenic tools in immunoenzymatic assays for detection of specific
anti-P. jirovecii antibodies (IgG and IgM) in sera of patients with (n = 48) and without
(n = 28) PcP. Results showed that only IgM anti-P. jirovecii levels were significantly
increased in patients with PcP compared with patients without P. jirovecii infection
(p ≤ 0.001 with both RSA). Thus, two strip lateral flow immunoassays (LFIA), based
on the detection of specific IgM anti-P. jirovecii antibodies in human sera samples,
were developed using the innovative association of P. jirovecii’s RSA with spherical
gold nanoparticles (AuNPs). For that, alkanethiol-functionalized spherical AuNPs with
ca. ˜40 nm in diameter were synthetized and conjugated with the two RSA (Msg
or Kex1) produced. These AuNP-RSA conjugates were characterized by agarose gel
electrophoresis (AGE) and optimized to improve their ability to interact specifically with
serum IgM anti-P. jirovecii antibodies. Finally, two LFIA prototypes were developed and
tested with pools of sera from patients with (positive sample) and without (negative
sample) PcP. Both LFIA had the expected performance, namely, the presence of a test
and control red colored lines with the positive sample, and only a control red colored
line with the negative sample. These results provide valuable insights into the possibility
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of PcP serodiagnosis at point-of-care. The optimization, validation and implementation
of this strip-based approach may help to reduce the high cost of medical diagnosis and
subsequent treatment of PcP both in industrialized and low-income regions, helping to
manage the disease all around the world.
Keywords: Pneumocystis pneumonia, gold nanoparticles, point-of-care, lateral-flow immunoassay, serological
diagnosis, major surface glycoprotein, kexin-like serine protease 1, synthetic recombinant antigens
INTRODUCTION
The fungus Pneumocystis jirovecii is a pathogen able to cause
a fatal pneumonia (PcP) in immunocompromised patients
worldwide (Barry and Johnson, 2001; Huang et al., 2011; Esteves
et al., 2014; Matos et al., 2017). In industrialized countries,
the incidence of PcP has decreased with the widespread use
of chemoprophylaxis and the introduction of combination
antiretroviral therapy, but it still remains a serious clinical
problem for human immunodeficiency virus (HIV)-infected
patients (Huang et al., 2011; Esteves et al., 2014; Matos et al.,
2017; European Centre for Disease Prevention and Control
(ECDC)/WHO Regional Office for Europe, 2018). Likewise,
the rising number of immunocompromised non-HIV-infected
patients susceptible to P. jirovecii infection in these countries,
warrants the need for improved diagnostic and treatment
strategies (Hughes, 2005; Roux et al., 2014). In developing
countries, where there is a lack of diagnostic resources and
expertise, the number of PcP cases reported have been increasing
significantly as more sensitive/specific laboratory methods are
being used (Chakaya et al., 2003; van Oosterhout et al.,
2007; Huang et al., 2011; Matos, 2012; Esteves et al., 2014;
Morrow et al., 2014).
Despite all the advances in understanding P. jirovecii
infection over the last years, in the twenty-first century
the standard diagnosis of this disease still depends on the
detection of P. jirovecii organisms through expensive and
laborious technologies (cytochemical or immunofluorescent
staining and/or PCR) applied to respiratory specimens obtained
by invasive techniques, such as bronchoscopy (Alanio et al.,
2016; Matos and Esteves, 2016; Matos et al., 2017; Tomás and
Matos, 2018). These standard diagnosis methods, besides being
difficult to implement in all economic settings, are not always
possible to perform in patients with respiratory failure or in
children (Alanio et al., 2016; Matos and Esteves, 2016; Matos
et al., 2017; Tomás and Matos, 2018). Therefore, to improve
disease management worldwide, there is a need to develop and
implement an alternative approach for the diagnosis of PcP that
can reduce associated costs, the need for invasive procedures, and
also improves response time and specificity.
Lateral flow immunoassays (LFIA) offer an easy solution to
these limitations as they are a simple, rapid and user friendly
technique, that do not require time-consuming instrumental
methods or technical expertise, allowing a low-cost point-of-care
alternative (Chan et al., 2013; Pöhlmann et al., 2014; Li et al., 2015;
Singh et al., 2015). Although LFIA is a well-recognized technique,
a specific serological biomarker for PcP diagnosis has not been
established (Morris and Masur, 2011; Esteves et al., 2015; Matos
and Esteves, 2016). Yet, reports of protection against acquisition
of infection by passive transfer of immune sera in mice (Gigliotti
et al., 2002) and by vaccination in immunosuppressed non-
human primates (Kling and Norris, 2016), triggers interest in
serum antibodies as serological biomarkers of the disease. In
addition, the suggestion that the IgM isotype has a predominant
role in shaping the earliest steps in recognition and clearance of
Pneumocystis infection both in mice (Rapaka et al., 2010) and in
humans (Djawe et al., 2010; Tomás et al., 2016), not only support
the role of antibodies in disease protection, but also highlights the
idea that a serological test for PcP diagnosis is viable.
As P. jirovecii’s major surface glycoproteins (Msg) are
characteristic of this microorganism and highly immunogenic,
containing both B and T cell protective epitopes (Stringer and
Keely, 2001), they are the obvious candidate to study serological
responses. In fact, promising studies using recombinant antigens
of this protein and antibody immunodetection techniques, have
shown that patients with PcP or previous episodes of PcP
present higher serum levels of anti-P. jirovecii antibodies than
patients without P. jirovecii infection or without previous PcP
events (Daly et al., 2004; Djawe et al., 2010; Gingo et al.,
2011; Blount et al., 2012; Tomás et al., 2016). However, as
Msg presents antigenic variation during infection as an evasion
mechanism (Kling and Norris, 2016; Hauser, 2019), other
antigenic candidates began to been explored. Pneumocystis
kexin-like serine protease 1 (Kex1) is one of them, because
it holds an antigenically stable active site peptide sequence
coded by a nuclear single-copy gene (Kutty and Kovacs, 2003;
Esteves et al., 2009), which avoids possible genetic variation.
Therefore, recombinant Kex1 antigens were also used to study
the humoral response to P. jirovecii, and the results suggest
that a high humoral response to this protein can be detected
and correlates with disease protection (Gingo et al., 2011;
Kling and Norris, 2016).
Taking this into consideration and knowing that measuring
the presence of biomarkers becomes quicker, more sensitive and
more flexible when nanoparticles are put to work as tags or labels
(Baptista et al., 2008; Baptista et al., 2011; Almeida et al., 2014),
led to the idea to develop an immunonanodiagnostic platform
for PcP diagnosis at point-of-care. Gold nanoparticles (AuNPs)
are the nanomaterial most commonly used in the development
of nanotechnology approaches for clinical diagnosis because of
their ability to form conjugates with biomolecules (e.g., proteins
and oligonucleotides) and due to their high surface area, stability
and intense color (Nagatani et al., 2006; Baptista et al., 2008;
Wilson, 2008; Franco and Pereira, 2013; O’Farrel, 2013; Almeida
et al., 2014). Thus, in this study, a bionanodiagnostic platform for
PcP diagnosis was developed associating recombinant synthetic
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antigens of P. jirovecii’s Msg and Kex1 with functionalized gold
nanoparticles, in order to improve detection of specific anti-
P. jirovecii antibodies in human sera samples.
This platform, illustrated in Figure 1, was developed using
AuNP-RSA conjugates to detect IgM anti-P. jirovecii antibodies
in patients sera, reactive to either of the RSA, in order to allow
less invasive biological specimens to be used in the diagnosis
of this infectious disease. These LFIA prototypes intends to
be specific, sensitive and accurate for PcP diagnosis, making a
highly relevant contribution to public health and economy in
industrialized countries and in communities with low-income
and lack of technology, helping to manage the disease worldwide.
MATERIALS AND METHODS
Production of P. jirovecii’s Recombinant
Synthetic Antigens (RSA) and Anti-RSA
Antibodies
RSA Production and Expression
The Msg RSA was designed as previously described (Tomás et al.,
2016) and Kex1 RSA followed the same procedure, studying
the immunogenicity of the P. jirovecii’s KEX1 longest gene
sequences available (GenBank: AY130996.1 and AY127566.1)
(Kutty and Kovacs, 2003). The putative reactive epitopes were
selected using bioinformatic tools to analyze electrochemical
properties, secondary structure prediction, polarity, relative
position to the membrane and hydrophobicity profile of the
specific polypeptides at the online software ExPASy – ProtScale
and CBS – TMHMM – version 2.0 (Dai et al., 2012, 2013;
Tomás et al., 2016). Only specific and conserved regions of
Pneumocystis KEX1 genes, presenting high similarity with the
sequences previously reported in GenBank for Pneumocystis’
Kex1 protein were considered for the final selection of the
RSA composition, through the NCBI blast tool. Regions with
high-predicted antigenicity and reactivity were chosen and DNA
oligonucleotides coding these regions (connected by pentaglycine
residues) were synthesized and cloned into the plasmid pHTP0
(Nzytech R©). The insert sequences were confirmed by sequencing
(Stabvida R©). After synthesis, each RSA was cloned into the
expression vector pLATE 31 (#K1261, Thermo Scientific R©),
following manufacturer’s instructions. This process enabled the
synthetic production of both RSA with a polyhistidine tail
end (6xHis), allowing their purification by immobilized metal
ion affinity chromatography (IMAC). These vectors were used
to clone CaCl2 competent E. coli XJb (DE3) cells by heat
shock. Cell pellets from 15 mL of IPTG-induced cultures
were re-suspended in 6 mL of lysis buffer (10 mM Tris-
HCl, 50 mM KCl, 1 mM EDTA, 0.2 mM PMSF, 500 mM
NaCl, 1% Triton X-100, 0.5% CHAPS, 2 mM CaCl2 and
0.02 µg.mL−1 DNAse I) and subjected to three cycles of a
freeze-thaw method. The supernatants were removed and the
pellets were re-suspended in 6 mL of 8 M Urea. An IMAC
purification system (HiTrap columns, GE Healthcare R©) packed
with a histidine chelating resin (Ni SepharoseTM 6 FastFlow,
GE Healthcare R©) was used. The column was balanced with
10 mL ligation buffer [20 mM Na2HPO4, 500 mM NaCl, 20
mM Imidazole (pH = 7.4)], then the sample containing the RSA
was applied. The column was washed with 10 mL of ligation
buffer, and the RSA were eluted with 20 mL of elution buffer
[20 mM Na2HPO4, 500 mM NaCl, 500 mM Imidazole, 5%
(v/v) glycerol (pH = 7.4)]. The eluted proteins were desalted
with a desalting membrane (D-0655, Sigma-Aldrich R©) into a
new buffer [20 mM Na2HPO4, 20 mM NaCl, 2% (v/v) glycerol
(pH = 7.4)], analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) on 15% acrylamide gels and
by indirect ELISA using anti-polyhistidine antibodies. Their
final concentrations were determined (NanoDrop 1000, Thermo
Scientific R©) before use.
Polyclonal Anti-RSA Antibodies Production
In order to produce antibodies able to recognize the RSA
produced, ascitic fluids containing polyclonal anti-RSA
antibodies were produced following the protocol of Ou
et al. (1993), with modifications. Briefly, after RSA purification,
50 µg of each RSA were emulsified in incomplete Freund’s
adjuvant plus peptide adjuvant and the emulsion was injected
intraperitoneally into five 5–6 weeks old BALB/c male mice
for each RSA. Subsequent immunizations with 50 µg of
RSA emulsified in incomplete Freund’s adjuvant, took place
at 2–3 weeks interval. After four inoculations, a test-bleed
(0.5 mL per animal) was tested by ELISA for titration.
When serum titers against the RSA were greater or equal
to 1:1000, an intraperitoneal injection of 1 × 106 cells of
sarcoma 180 cell line was performed in each mouse, to
obtain high titer polyclonal ascitic fluids. When a 20–25%
increase in body weight of each mouse was recorded (caused
by the ascite), they were euthanized and the ascitic fluids
were collected and quantified (NanoDrop 1000, Thermo
Scientific R©). These fluids will be referred throughout this work as
“AuNP-RSA antibodies.”
All animals used in the study were housed and cared for
under the guidelines set forth in the Guide for the Care and
Use of Laboratory Animals. Good animal handling practices
were used and all European Directives were followed, namely
the Portuguese DL 113/2013. Experiments were conducted
by people certified by the Portuguese national body for
experimental animal manipulations “Direcção Geral de
Alimentação e Veterinária” (DGAV). The facilities at Instituto
de Higiene e Medicina Tropical/Universidade Nova de Lisboa
(IHMT/UNL) animal house, procedures for maintenance
and care of animals as well the experimental scheme used
(immunization, blood collection, spleen removal, and euthanasia
procedures) are accredited by the Portuguese DGAV and in
accordance with relevant guidelines and regulations of the ethical
committee of IHMT/UNL.
Human Serum Specimens
This study retrospectively analyzed sera from 76 HIV-infected
patients with respiratory symptoms attending hospitals in the
Lisbon area, between 2010 and 2018. Their bronchoalveolar
lavage (BAL) specimens were submitted to the Group of
Opportunistic Protozoa/HIV and Other Protozoa of Instituto
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FIGURE 1 | Illustration of LFIA strips developed in this study, showing its various components and the expected results in positive and negative tests. In a positive
test, AuNP-RSA conjugates will bind to IgM anti-P. jirovecii antibodies present in the serum of infected patients, forming a complex that is captured by the
immobilized anti-human IgM in the test line that becomes red colored. AuNP-RSA conjugates in excess will continue to migrate from the test line to the control line,
where immobilized anti-RSA antibodies will capture them, giving rise to a second red line. In the negative test, as IgM anti-P. jirovecii antibodies are absent in the
patient’s serum, no complex is formed with AuNP-RSA conjugates, which precludes the interaction with anti-human IgM antibodies, preventing the color formation
at the test line (no color). In the control line, the AuNP-RSA conjugates will be captured by the immobilized anti-RSA antibodies, giving rise to a red line.
de Higiene e Medicina Tropical (Lisboa, Portugal) with the
purpose of routine diagnosis of PcP with the patients’ informed
consent and according to the routine institutional procedures.
The diagnosis of PcP was confirmed in 48 patients by
visualization of the organism in BAL specimens using indirect
immunofluorescence with monoclonal antibodies (IF/MAb)
(MONOFLUO Pneumocystis jirovecii, BioRad R©) and/or by
P. jirovecii’s DNA detection through nested-PCR (nPCR)
from the locus mtLSUrRNA, after DNA extraction (QIAamp,
QIAGEN R©). Twenty-eight patients whose specimens were
negative for P. jirovecii were considered not infected (without
PcP). All patients’ demographic data were kept confidential and
coded for the research team.
All selected patient’s sera samples were analyzed through
indirect ELISA for detection of circulation anti-P. jirovecii
antibodies. Then, the optimization of AuNP-RSA conjugates
interaction with anti-P. jirovecii antibodies was performed
creating a pool of positive sera (positive sample) and a pool of
negative sera (negative sample) using five serum specimens from
patients with and without P. jirovecii infection, respectively.
The Instituto de Higiene e Medicina Tropical (Lisboa,
Portugal) ethics committee approved the study’s protocol and
waived informed consent as a retrospective observational study.
ELISA for Detection of Anti-P. jirovecii’s
Antibodies
The purified RSA were applied individually as antigenic tools in
indirect ELISA to detect IgG and IgM anti-P. jirovecii in patient’s
sera. Odd (test) column wells of the microtiter plate were coated
overnight at 4◦C with 50 µL of the RSA diluted to 5 µg.mL−1 in
0.05 M carbonate buffer (pH = 8.4). Even (blank) columns wells
were coated in the same conditions with PBS 1x. After coating,
the wells were washed once with PBS and blocked with 70 µL
of 1% polyvinyl alcohol (PVA) for 1 h at room temperature (20–
25◦C). After blocking, PVA was removed from the plate without
washing. Duplicates of each serum sample were analyzed in a test
and blank well, under conditions (dilution, incubation time and
temperature) determined by the Ig class to be detected and the
RSA used as antigenic tool, being the specific protocols presented
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at Table 1. Finally, the optical densities (OD) were measured
at 405nm and the mean OD of the blank wells was deducted
to the mean OD of the test wells to obtain the final OD value
for each sample.
Mann-Whitney-U non-parametric tests were used to examine
the differences between the distribution of antibody titers in
different patient categories with a significance level of 0.05, using
the Statistical Package for Social Sciences (SPSS) version 20.0.
Synthesis and Functionalization of
Spherical Gold Nanoparticles
For synthesis and functionalization of gold nanospheres, all
glassware was washed with aqua regia and rinsed thoroughly
with deionized water followed by ultrapure water (18.2
M·cm−1) before use.
Citrate capped spherical gold nanoparticles (AuNPs) were
synthesized following a method previously described (Bastús
et al., 2011). Briefly, 150 mL of a 2.2 mM citrate solution (1.06448,
Merck R©) was heated using an oil bath, under stirring. After the
reflux was stablished, 1 mL of a 25 mM gold (III) chloride solution
(484385, Sigma R©) was added to the reaction vessel and let to react
for 10 min. After these steps, a seeds suspension was obtained.
Then, the resultant suspension was cooled down to 90◦C, keeping
the condenser fitted and the stirring conditions. An extra 1 mL of
the same gold (III) solution was added and let to react for 30 min.
After this period, this last step was repeated.
Later, the citrate capping was replaced by functionalization
of the AuNPs with 11-mercaptoundecanoic acid (11-MUA,
450561, Aldrich R©). This step involved adding 10 mM 11-MUA
ethanolic solution, to attain a 11-MUA:AuNP ratio of 30,000.
After an overnight incubation, the AuNPs were washed (3000 g
for 30 min) to remove free 11-MUA in solution. The highest
volume possible of supernatant was discarded and the pellet was
resuspended in ultrapure water up to ∼5% of the initial volume.
The final suspension was stored in the dark until use.
AuNPs were characterized by ultraviolet-visible spectroscopy
(UV-Vis) before and after functionalization and by dynamic
light scattering (DLS), electrophoretic light scattering (ELS) and
nanoparticle tracking analysis (NTA) after the functionalization
process. UV-Vis was performed in a Varian Cary 50 Bio
spectrophotometer, using a quartz cell, with the suspension
at an appropriate dilution. DLS and ELS measurements were
performed three times for the same sample at 25◦C, with light
detection at 273◦ (DLS) and at 17◦ using the backscatter mode
(ELS) of the Malvern Zetasizer NanoZS equipment. NTA was
performed in a Malvern Nanosight NS300 (with a 642 nm
laser module), with the analysis of 5 videos of 1 min each,
captured in 5 different portions of the sample (still mode). These
measurements were then merged in a single size distribution.
Conjugation of AuNPs With the RSA
The antigen concentration to use in the conjugation process
to guarantee the maximum coverage of the AuNPs surface
but also the colloidal stability of the AuNP-RSA conjugates
was optimized. For that purpose, AuNP-Msg and AuNP-
Kex1 conjugates were formed through electrostatic interactions
established between increased molar ratios of each RSA and
the AuNPs in solution, as described previously (Guirgis et al.,
2012; Cavadas et al., 2016; Almeida et al., 2018). A solution
of 0.06nM AuNPs was incubated overnight (≈15 h) at 4◦C
with molar ratios ranging from 0 to 5000 of Msg and Kex1
stock solutions of 0.16 and 0.11 mg.mL−1, respectively. After
conjugation, non-bound RSA were removed by centrifugation
(5800 g for 5 min), separating the pellets containing the AuNP-
RSA from the supernatant, to perform agarose gel electrophoresis
(AGE). Agarose gels (0.3%) were prepared by heating agarose
in TAE buffer (0.125 × pH = 8.4), and allowing the gel
to form at room temperature. The AuNP-RSA conjugates
pelleted after centrifugation were re-suspended in 13.5 µL of
phosphate buffer (5 mM Na2HPO4, pH = 7.4) and 1.5 µL of
glycerol (99%, Nzytech R©) prior to loading. The gels were run
at constant voltage of 180 V with a 21 cm electrode spacing
for 20 min in TAE 0.125 × using the E865 CONSORT power
supply. Digital pictures were acquired (WAS-LX1A Huawei
P10 Lite camera) and processed through eReuss software (a
gel analysis application freely available at https://github.com/
lkrippahl/eReuss), providing an accurate measurement of the
red bands migration in agarose, which allows the calculation
of their electrophoretic mobility (Ferard, 1994; Almeida et al.,
2018). Electrophoretic mobility [µ (µm.cm/V.s)] is defined as the
observed rate of migration of a component [ν (µm/s)] divided
by the electric field strength [E (V/cm)] in a given medium.
In the case of AGE, a solid support medium, only apparent
values can be determined (Ferard, 1994). Thus, the molar ratio in
which the AuNP-RSA electrophoretic mobility reaches a plateau,
corresponding to saturation of the AuNP surface with each RSA,
was selected through duplicate experiments.
Analysis of Human Sera Interaction With
AuNP-RSA by Agarose Gel
Electrophoresis
To avoid unspecific antibody binding to the AuNP-Msg
and AuNP-Kex1 conjugates, bovine serum albumin (BSA)
(AppliChem R©) and Casein (Sigma R©) were studied as blocking
agents. A BSA and Casein stock solution at 1 mg.mL−1 were
added to 0.06 nM AuNP-RSA conjugates in solution at increased
molar ratios ranging from 0 to 10 with AuNP-Kex1 conjugates
and from 0 to 50 with AuNP-Msg conjugates, producing AuNP-
RSA-BSA and AuNP-RSA-Casein conjugates. The incubation was
performed during 90 min at 4◦C, the non-bound blocking agents
were removed by centrifugation (5800 g for 5 min) and the pellets
prepared for agarose gel electrophoresis. Similarly to what was
done with the AuNP-RSA conjugates, the molar ratio plateau was
selected through duplicate experiments for each blocking agent.
An optimal molar ratio of human serum was established in
the same way, incubating 0.06 nM solutions of AuNP-RSA-
Casein and AuNP-RSA-BSA conjugates with molar ratios ranging
from 0 to 7.5 of the positive sera pool (80 mg.mL−1). The
molar ratio in which the optimal coverage of the conjugate was
obtained, was selected.
These serum molar ratios were applied in an AGE assay, where
0.06 nM AuNP-RSA solutions and 0.06nM AuNP-RSA-BSA
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TABLE 1 | ELISA protocols and conditions for detection of IgG and IgM anti-P. jirovecii antibodies reactive against the RSA produced.
Protocol RSA applied as antigenic tool
Kex1 Msg
Application of 50 µL of serum diluted in
PBS with 0.05% tween-20 and 5% BSA
1/20 1/40 1/60 1/140
Incubation 1 h at 37◦C
Washing 4x with PBS with 0.05% tween-20
1x with distilled water
Application of 50 µL of anti-human
immunoglobulin M (A2189, sigma§) diluted
in PBS with 0.05% tween-20
1/1000 1/4000
Application of 50 µL of anti-human
immunoglobulin G (A2064, sigma§) diluted
in PBS with 0.05% tween-20
1/3000 1/4000
Incubation 1 h at 37◦C
Washing 4x with PBS with 0.05% tween-20
1x with distilled water
Application of 50 µL of substrate 4-nitrophenylphosphate sodium salt (1 mg.mL−1)
Incubation Overnight at 4◦C Overnight at 4◦C Overnight at 4◦C 2 h at 37◦C
and AuNP-RSA-Casein conjugates solutions were incubated for
90 min at 4◦C with and without the human positive and negative
sera pools. After incubation, the non-bound serum was discarded
after centrifugation (5800g for 5 min) and the electrophoretic
mobility of each conjugate was established. This assay was
performed in triplicate and the analysis of the differences between
the electrophoretic mobility of each conjugate formed was
evaluated and used to established the optimal conjugate (AuNP-
RSA or AuNP-RSA-BSA or AuNP-RSA-Casein) to be used in the
LFIA development.
Assembly of LFIA Strips for Detection of
IgM Anti-P. jirovecii Antibodies in Human
Sera
For LFIA development, a starter kit from Advanced
Microdevices, Ambala Cantt, India, was used. This kit offers: two
types of cellulose fiber absorbent pads with different thickness
(AP-045 with 0.4 mm and AP-080 with 0.8 mm); three types of
nitrocellulose membranes (NM) fixed on a plastic backing, with
different protein binding capacities (type CNPF, a low protein
binding membrane with pore sizes of 8 and 10 µm; type CNPC,
a high protein binding membrane with pore sizes of 12 and 15
µm; and type CNPH, the highest protein binding membrane
with wicking times of 70, 90, 150, and 200 s); two glass fiber
sample pads, one without any specific pre-treatment (GFB-R4)
and a second one pre-treated with buffers and detergents to
help prevent non-specific binding of sample components to
the pad (GFB-R7L); and two conjugate pads, a polyester matrix
without any specific pre-treatment (PT-R5) and another one pre-
treated with buffers for uniform movement of gold nanoparticle
conjugates (PT-R7).
Absorbent Pad and Membrane Selection
To perform this selection, dipsticks composed by the
nitrocellulose membrane (NM) and the absorbent pad were
tested. Membranes were manually cut into 6 × 0.5 cm sections.
The control and test lines were spotted manually, in a circle or
in a line, by depositing 0.03 mg.mL−1 of anti-RSA antibodies
(anti-Msg or anti-Kex1, depending on the RSA present in the
conjugate) and 0.001 mg.mL−1 of anti-human IgM antibodies
(I-0759, Sigma R©), respectively. Different dilutions in Tris buffer
(10 mM Tris-HCl, pH = 7) for the control antibodies, ranging
from 0 to 1/4, and for the test antibodies, ranging from 0 to
1/10, were studied. The membranes dried for 30 min at room
temperature before use. A blocking process of the membranes
was also tested with an additional step of 30 min incubation at
room temperature with skin milk (2%, Sigma R©), followed by
three washes with PBS with 0.05% Tween-20 and dried at 37◦C
during 30 min. At the top of the membrane, a 3× 0.5 cm section
of absorbent pad (AP-045 or AP-080) was attached with 1–2 mm
overlapping with the membrane. A solution of 0.72 nM AuNP-
RSA-Caseín conjugates was incubated with appropriate molar
ratio of positive serum for 90 min at 4◦C and then, the dipsticks
composed by the NM and the absorbent pad were immersed into
50 µL of this solution in a tube, with the absorbent pad side up
for 2 min. Driven by capillary forces, the liquid migrated up the
membrane into the absorbent pad. The selection of the optimal
set of membrane/absorbent pad was based on visually inspection
of test and control line results.
Conjugate Pad, Sample Pad and Sample Buffer and
Dilution Selection
To perform this selection, full LFIA strips were assembled and
tested. Conjugate release pads available were manually cut into
1 × 0.5 cm sections and tested with and without pre-treatment
with PBS containing 5% sucrose, 1% BSA and 0.5% Tween 20.
Then, they were saturated with 15µL of conjugate concentrations
ranging from 0.2 to 4.6 nM. These conjugate pads dried for 2
h at 37◦C before assembling to the membrane/absorbent pad
set (see above) and then attached to the bottom of the strip (at
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the origin of the sample flow), with 1–2 mm overlapping with
the membrane. The sample pads were also manually cut into
3 × 0.5 cm sections and tested with and without prior saturation
with 0.03% anti-human immunoglobulin G (2040-04, Sigma R©)
and dried overnight at room temperature, before assembling at
the bottom of the strip, overlapping almost completely with the
conjugate pad. After the whole LFIA strip was assembled, 200 µL
of positive serum diluted from 0 to 1/100 into phosphate buffer
(5 mM Na2HPO4, pH = 7.4), phosphate buffer with 0.05% BSA
and 0.05% Tween-20, phosphate buffer with 1% BSA and 1%
Tween-20 or PBS with 0.05% Triton-X-100, was added to the
sample pad. Driven by capillary force, the sample migrated up
the sample pad to the conjugate pad and to the membrane into
the absorbent pad. After 10 min, the selection of the optimal set
of conjugate pad/sample pad and optimal sample buffer/dilution
conditions was based on a visually inspection of test and control
line results, on the manufacturer’s recommendation for the
uniform movement of gold nanoparticles conjugates and on
quantification of color intensity in test and control lines.
Quantification of Color Intensity
The quantification of color intensity in test and control lines
was made in strips tested before and after pre-treatment of
conjugate/sample pads, in strips tested with different positive
sample dilutions and in strips tested with the final optimal
conditions. Digital pictures of the optimized strips were
acquired (WAS-LX1A Huawei P10 Lite camera) and eReuss (a
gel analysis application freely available at https://github.com/
lkrippahl/eReuss) parameters were adapted for color intensity
quantification. To set the image processing, in the band color
droplist of the software, the average color of the test and control
lines was selected, forcing the software to ignore the color channel
in which the lines have a light intensity closer to the background.
This step ensures that the intensity value given by the software
for each line results from the previous elimination of the
background. Then, in the image clipping set, the NM region with
both test and control lines results was selected for processing. The
software, for each defined vertical strip, sums the color intensity
of the pixels in horizontal sections giving a plot with the heights
of each point per line. In band profiling step, the conditions in
which we intend to measure the peaks of color intensity in the
different control/test lines were set. Two Gaussians were fitted
per strip, one for each test or control line, with a minimum height
value of 5% of the image brightness range, to set the cut-off value
of intensity. The remaining parameters were left with the default
settings. The software identified the peaks by iteratively fitting
a Gaussian distribution to the maximum intensity value in the
curve, subtracting that distribution and repeating until either the
number of Gaussians was reached or the maximum value falls
below the minimum height parameter. A final report with the
summarized results was obtained and analyzed for selection of
the optimal sample dilution and the need for sample/conjugate
pad pre-treatments.
LFIA Strips Testing With Clinical Samples
The viability of the prepared immunochromatographic strips
as tools for detection of anti-P. jirovecii antibodies was tested,
in triplicate experiments, by loading human serum pools from
patients with and without PcP.
In the case of strips in which the conjugates were composed
by AuNP-Msg-Casein, 200 µL of positive/negative human serum
pools, diluted 1:50 in phosphate buffer with 0.05% BSA and 0.05%
Tween-20, were added to the sample pad. In strips with adsorbed
AuNP-Kex1-Casein conjugates, 200 µL of positive/negative
human serum pools, diluted 1:20 in phosphate buffer with
0.05% BSA and 0.05% Tween-20, were used instead. Driven by
capillary forces, the samples migrated up the conjugate pad to the
membrane into the absorbent pad and, during 10 min, the test
results were evaluated visually. Further quantification of color
intensity in test and control lines of each strip was performed
using the eReuss software.
RESULTS
Design, Expression, and Purification of
Msg and Kex1 RSA
The Msg RSA was designed as previously described
(Tomás et al., 2016).
The Kex1 RSA consists of 110 amino acids composed by
three regions with high-predicted antigenicity and reactivity
from P. jirovecii’s Kex1 entire sequence (see Supplementary
Figures S1–S6), that were chosen and synthesized interconnected
by two “linkers” of five glycine residues and expressed with a
tail of six residues of histidine. In this RSA, epitope 1 is coded
by Kex1104−134 amino acids, epitope 2 by Kex1467−501 amino
acids and epitope 3 by Kex1725−758 amino acids, according to
GenBank accession numbers AAN12365.1 and AAM97495.1 (see
Supplementary Figure S7; Kutty and Kovacs, 2003).
The SDS-PAGE analysis showed that both RSA were expressed
with their predicted molecular sizes (16.7 kDa for Msg RSA and
22 kDa for Kex1 RSA) after IPTG induction (Figures 2A,B) and
that they were successfully purified by immobilized metal-ion
affinity chromatography (IMAC) (Figure 2C). Indirect ELISA
using anti-polyhistidine antibodies were performed to optimize
the purification process, ensuring that the RSA were detected
during the elution phase and not during column washing after
sample application (see Supplementary Figure S8).
Detection of Serum Anti-P. jirovecii
Antibodies
Two different IgG and IgM ELISA were developed, according to
the protocols presented in Table 1, using Kex1 RSA and Msg RSA
as coating antigens. The results of the distribution of the IgG and
IgM anti-P. jirovecii levels across patients with PcP and without
P. jirovecii infection are represented in Figure 3.
Both RSA showed applicability in the detection of specific
IgG and IgM anti-P. jirovecii antibodies. However, IgG ELISA
showed inability to distinguish patients with PcP from patients
without P. jirovecii infection as the median levels of the Igs
detected in these patient’s groups were not statistically different
(p > 0.05). Yet, IgM ELISA with both Kex1 RSA and Msg
RSA demonstrated ability to distinguish patients with the disease
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FIGURE 2 | Assessment of the RSA expression and purification process.
SDS-PAGE profiles of non-induced (1) and induced (2) E. coli XJb (DE3) cells
transformed with the expression vector with the Kex1 RSA (A) and the Msg
RSA (B); and SDS-PAGE profiles of purification products of the Msg RSA and
Kex1 RSA, after IMAC protocol (C). Two different protein molecular weight
standards were used, the Roti§ -Mark standard from Carl-Roth§ (M1) and one
produced “in house” (M2). The bands of interest and their theoretical
molecular weight are highlighted (16.7 kDa for Msg RSA and 22 kDa for Kex1
RSA).
from patients without P. jirovecii infection. With the Kex1
RSA, the median levels of IgM anti-P. jirovecii detected by
ELISA was 0.3871 in patients with PPc and 0.0997 in patients
without P. jirovecii infection, which were considered statistically
different (p < 0.002). With the Msg RSA, the differences
between the median levels of IgM anti-P. jirovecii detected
by ELISA in patients with and without the disease were also
considered statistically significant (p = 0.001), and the values
were 0.6076 in patients with PPc and 0.4195 in patients without
P. jirovecii infection.
Characterization of Gold Nanoparticles
Gold nanoparticles were characterized by UV-Vis,
DLS, ELS, and NTA.
The UV-Vis spectrum of the citrate-capped AuNPs (as
synthesized) shows a localized surface plasmon resonance (LSPR)
band with its maximum at 526 nm. From the UV-Vis spectrum
data (AbsLSPR and Abs450), it was determined that the batch of
AuNPs had a concentration of 0.2 nM with an average size of
39 nm (Haiss et al., 2007). After functionalization with 11-MUA
(see Supplementary Figure S9A) the hydrodynamic size data
obtained from DLS showed a Z-Average of 46.2 ± 0.2 nm. The
zeta-potential value obtained by ELS was -36± 1 mV, indicating a
high colloidal stability. The hydrodynamic diameter distribution
obtained by NTA (see Supplementary Figure S9B), presented an
average of 51.0± 3.8 nm and a mode of 41.7± 2.9 nm. The mode
is down shifted by 9.3 nm compared to the average, since the
aggregates (especially noticeable in the distribution between 60
and 90 nm) contribute for the mean value.
Gold Nanoparticle-P. jirovecii’s RSA
Conjugates (AuNP-RSA)
The functionalized AuNPs produced were conjugated to Msg
(AuNP-Msg) or Kex1 (AuNP-Kex1) RSA of P. jirovecii, in
order to synthesize probes for the detection of IgM anti-
P. jirovecii antibodies in sera of patients with PcP. Agarose
gel electrophoresis assays were used to characterize the AuNPs
before and after conjugation with the RSA (Guirgis et al.,
2012; Cavadas et al., 2016; Kim et al., 2016; Almeida et al.,
2018). As shown in Figures 4A,C, the migration distance of
the RSA-conjugated particles (AuNP-Msg and AuNP-Kex1),
compared to the non-conjugated AuNPs, decreases as the
RSA:AuNP ratio increases. However, when the amount of RSA
reached 175.5 nM (ratio 2925:1), the addition of more RSA
no longer decreased significantly the mobility of the conjugates
and a plateau began to form. Therefore, a RSA:AuNP ratio of
2925:1 was stablished as the optimum to produce AuNP-RSA
conjugates in which RSA molecules fully cover the AuNPs. For
these RSA:AuNP ratios of 2925:1, the difference between the
calculated electrophoretic mobility (1µ) of AuNP alone and
AuNP-RSA conjugates was 0.46 ± 0.01 µm.cm/V.s for AuNP-
Msg conjugates and 0.42 ± 0.02 µm.cm/V.s for AuNP-Kex1
conjugates (Figures 4B,D).
Blocking of AuNP-RSA Conjugates for
Reaction With Human Sera
In order to avoid unspecific interactions with human sera,
increasing the specificity of the interaction between the
conjugates and the target antibodies, blocking of the AuNP-
RSA conjugates was assessed with BSA or with casein, two well
know proteins used routinely for this purpose in immunoassays
(Binder and Isler, 2013). The electrophoretic mobility of AuNP-
Msg conjugates incubated with increasing ratios of BSA or
casein was determined by AGE (see Supplementary Figure S10).
A plateau was observed for a BSA:AuNP-Msg ratio of 20, so
that value was chosen for future experiments. In the case of
AuNP-Kex1 conjugates, since there is no observable interaction
of the blocking agents with these conjugates, no particular
BSA:AuNP-Kex1 and Casein:AuNP-Kex1 ratios were found
(see Supplementary Figure S11). However, to evaluate the
interaction of human sera with conjugates with and without
blocking agent, a ratio of 2:1 of casein to AuNP-Kex1 was used.
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FIGURE 3 | Boxplots with IgG and IgM anti-P. jirovecii levels results across patients with PcP and patients without P. jirovecii infection. Simple boxplots showing the
reactivity levels (OD at 405 nm) of IgG and IgM anti-P. jirovecii antibodies detected by ELISA protocols applied with the Kex1 RSA (A) and Msg RSA (B) as coating
antigens, in all sera specimens of patients analyzed in the study. The statistic values (p) representing the statistical significant difference from Mann Whitney-U tests
performed between patient’s groups are presented.
The blocked and unblocked AuNP-RSA conjugates were
further assessed by AGE to characterize their ability to interact
with human sera from patients with and without P. jirovecii
infection. Based on the same type of AGE experiments, in
which several molar ratios of the positive human serum pool
to blocked AuNP-RSA conjugates were evaluated, a human
serum ratio of 4.55 was selected for further experiments
(see Supplementary Figures S12, S13).
AuNP-RSA, AuNP-RSA-BSA, and AuNP-RSA-Casein
conjugates were incubated with and without positive
(PosSerum) and negative (NegSerum) serum pools at the
selected ratio and then assessed by AGE (see Supplementary
Figure S14). Results suggest that there were still free spaces
on the surface of the AuNP-Msg conjugates that were
blocked by casein and by BSA, causing a decrease in the
electrophoretic mobility of the conjugates in the absence
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FIGURE 4 | AuNP-RSA conjugates formation. Agarose gel electrophoresis at increasing ratios of Msg RSA to AuNPs (A) and Kex1 RSA to AuNPs (C), showing the
migration of each conjugate bands toward the positive electrode. Differences between the electrophoretic mobility of the AuNPs alone and AuNP-Msg (B) or
AuNP-Kex1 (D) conjugates at increasing ratios, calculated from the migration distances in gel. The nine ratios (162.5–5000) correspond to protein concentrations of
9.75, 15, 19.5, 39, 58.5, 117, 175.5, 234, and 300 nM. Standard deviation bars correspond to duplicate experiments.
of serum (see Supplementary Figures S14A,B). However,
in the case of AuNP-Kex1 conjugates (see Supplementary
Figures S14C,D), the electrophoretic mobility of the conjugates
before serum interaction, is very similar in the presence or
absence of any blocking agent, which reinforces the idea
that the blocking step is not as crucial for these AuNP-
Kex1 conjugates as it is for the AuNP-Msg conjugates, as
previously observed (see Supplementary Figures S10, S11).
Nevertheless, the blocking step was maintained for both
AuNP-RSA conjugates, in order to avoid the event of non-
specific interactions with human sera components. For this
purpose, casein appeared to be more effective, as non-specific
interactions between the negative serum and the conjugates
were lower in the presence of this blocking agent than in
the presence of BSA. That can be verified by a decrease
in the migration shift between the blocked conjugates,
before and after interaction with the negative serum (see
Supplementary Figure S14: a shift of 0.13 µm.cm/V.s in
AuNP-Msg-Casein conjugates against a shift of 0.42 µm.cm/V.s
in AuNP-Msg-BSA conjugates; a shif of 0.23 µm.cm/V.s in
AuNP-Kex1-conjugates against a shift of 0.39 µm.cm/V.s in
AuNP-Kex1-BSA conjugates).
Interaction Between Human Sera and
AuNP-RSA-Casein Conjugates
The interaction between AuNP-RSA-Casein conjugates and
human sera from patients with and without P. jirovecii infection
was assessed by AGE and is represented in Figure 5. Results
shows a consistent detection of a migration shift between
AuNP-RSA-Casein conjugates that interacted with sera from PcP
patients and conjugates that interacted with sera from patients
without P. jirovecii infection (0.31 µm.cm/V.s in the case of
AuNP-Msg-casein conjugates and 0.79 µm.cm/V.s in the case of
AuNP-Kex1-casein conjugates). The presence of these shifts in
AGE assays are a proof-of-concept for the LFIA to be developed:
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FIGURE 5 | Interaction of AuNP-Msg-Casein (A,B) and AuNP-Kex1-Casein
conjugates (C,D) with sera pools from patients with and without P. jirovecii
infection. (A,C) Agarose gel electrophoresis of AuNP-RSA-Casein conjugates
before interaction with serum (1) and after interaction with positive (2) and
negative (3) serum samples. (B) Electrophoretic mobility of the
AuNP-RSA-Casein conjugates before interaction with human sera (No Serum)
and after interaction with the positive human sera (PosSerum) and negative
human sera (NegSerum). Shifts (µm.cm/V.s) between blocked conjugates
with positive and with negative sera are indicated, evidencing the binding of
antibodies present in the positive serum. Standard deviation bars correspond
to triplicate experiments.
in fact, anti-P. jirovecii antibodies present in PcP patient’s sera
specifically interact with both RSA, binding to the AuNP-RSA-
Casein conjugates and decreasing their migration distance in
the gel. Additionally, no significant interactions between AuNP-
RSA-Casein conjugates and non-infected patient’s sera occur,
since the migration distance of these conjugates before and after
contact with the negative sample is similar, considering all the
experiments performed.
Results also show that the distance migration shift between
conjugates that interact with the positive sera and conjugates
that interact with negative sera is bigger in the presence of
AuNP-Kex1 conjugates (up to 2.5x), suggesting that this RSA is
a better antigenic tool for anti-P. jirovecii antibodies detection
than the Msg RSA.
Assembly and Optimization of LFIA
Strips Using AuNP-RSA-Casein
Conjugates
For LFIA strips development, a commercial starter kit was used
(see section Materials and Methods for a detailed description
of the components). LFIA’s components selection was based on
manufacturer’s advices and visual inspection of test and control
lines results (data not shown).
Absorbent Pad and Membrane Selection and
Optimization
By visual inspection, it was observed that all NM can be
used successfully without a previous blocking step. Additionally,
the signal in the control and test lines appeared to increased
proportionally with pore diameter and the wicking time of the
NM. However, as membranes type CNPH are presented by
the manufacturer as the NM with the highest protein binding
capacity, the one with the longest wicking time (200 s) was the
one chosen for the LFIA development.
No visual differences were noted in CNPH200 NM dipsticks
results using one or the other absorbent pad available in the
kit. However, as absorbent pad 045 is thinner, it allows a slower
migration along the NM, which may improve the number of
interactions in the control and test lines. Therefore, it was the
absorbent pad selected for LFIA development.
The selection of the control and test antibodies dilutions
was made in order to obtain uniform signals in both lines. By
visual inspection (data not shown), a dilution of 1/2 in Tris
buffer for the control antibodies and no dilution for the test
antibodies were selected.
Conjugate and Sample Pad Selection and
Optimization
In the case of conjugate pads available, as the manufacturer states
that the PT-R7 pad was pre-treated for uniform movement of
gold nanoparticles conjugates, unlike the PT-R5 pad, the PT-
R7 pad was the one selected. Concerning the AuNP-RSA-Casein
conjugates concentration to be used, a colloidal solution of 2.4
nM was stablished as sufficient to provide a visual interpretation
of the test results (data not shown).
Regarding the sample pad selection, as GFB-R7L pads were
pre-treated by the manufacturer with detergents and buffers that
decreased sera non-specific binding to the pad, they allowed
better visual interpretation of the results than the GFB-R4
untreated pad, and that’s why GFB-R7L pad was the one chosen.
To improve signal intensity on both test and control lines, pre-
treatments of the selected conjugate pad (with a buffer containing
sucrose, BSA and Tween 20) and sample pad (with anti-human
immunoglobulin G) were performed. The color intensity of
test/control lines in strips before and after treatment was assessed
visually and quantified by the eReuss software, and the results
are presented in Figure 6. Results show that pre-treatments
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FIGURE 6 | Comparative analysis of the results from LFIA strips containing AuNP-Msg-Casein conjugates (A,B) and AuNP-Kex1-Casein conjugates (C,D) in the
presence (after treatment) and absence (before treatment) of conjugate and sample pad pre-treatments. (A,C) Digital pictures of strips before and after conjugate
pad treatment with a buffer (5% sucrose, 1% BSA and 0.5% Tween 20) and sample pad treatment with 0.03% anti-human immunoglobulin G. From bottom to top,
strips were composed by the sample pad, the conjugate pad, the nitrocellulose membrane with the test (T) and control (C) lines and the absorbent pad. (B,D)
Quantification of color intensity of the control and test lines, where the intensity shown in each line corresponds to the maximum height of the Gaussian line fitted by
eReuss software.
Frontiers in Microbiology | www.frontiersin.org 12 December 2019 | Volume 10 | Article 2917
fmicb-10-02917 December 18, 2019 Time: 16:9 # 13
Tomás et al. Gold-Based Immunonanodiagnosis of Pneumocystis Pneumonia
steps enhanced visual signal of both test and control lines
(Figures 6A,C), which was confirmed by color quantification,
showing higher peaks of color intensity in both lines after these
treatments (Figures 6B,D).
Sample Buffer and Dilution Selection
By visual inspection of strip results (data not shown), phosphate
buffer with 0.05% BSA and 0.05% Tween-20 was selected as
the optimal sample buffer. Then, final dilutions of 1:50 and
1:20 of sera samples were established as optimal for LFIA
with AuNP-Msg-Casein conjugates and AuNP-Kex1-Casein
conjugates, respectively, through visual inspection and color
intensity quantification of strip test results, represented in
Figure 7. Although higher color intensities were expected at
lower sample dilutions, these results were reproducible and
may be associated with an agglutination phenomenon, further
addressed in the Discussion section.
Optimized LFIA Strips Testing With
Human Sera Pools
After optimization, LFIA strips were tested with sera pools from
patients with (positive sample) and without (negative sample)
PcP, in triplicate experiments (see Supplementary Figure S15).
Visually, 3 min after sample addition it was already possible to
detect the presence of a colored line in the control zone on strips
with the negative sample and two colored lines, in the control
and test zones, on strips with the positive sample. The results
remained invariable 10 min after the end of the elution process,
i.e., solvent reaching the absorbent pad (Figures 8A,C).
The software used for color intensity analysis was unable to
detect color on the test lines of the strips with negative samples,
and detect similar color intensity for the control and test lines on
the strips with positive samples (Figures 8B,D).
DISCUSSION
Nowadays, there is a demand to find point-of-care diagnostic
tests that enable fast and inexpensive screening/diagnosis
of infectious diseases, to improve disease control and
retrenchment of healthcare systems costs worldwide. In the
case of Pneumocystis pneumonia, in which there are no specific
clinical, radiologic or gasometric findings and none of the
serologic biomarkers studied until now showed to be highly-
specific of the disease (Morris and Masur, 2011; Esteves et al.,
2015; Matos and Esteves, 2016; Tomás and Matos, 2018),
this has been a challenge. Thus, current diagnosis techniques
depend on the direct or indirect detection of the pathogen in
respiratory specimens, which makes them dependent on costly
and invasive procedures.
Recently, studies showed that a technology based on synthetic
amino acid sequences, designed to hold more than one reactive
region of the selected antigens, could enhance the immunological
diagnosis of Toxoplasma gondii (Dai et al., 2012, 2013).
Therefore, in our previous study, this research group designed
a recombinant synthetic antigen (RSA) with three antigenic
regions of the Msg protein, in order to standardize and enhance
the detection of reactive antibodies against P. jirovecii (Tomás
et al., 2016). In this single antigenic tool, several proven reactive
and conserved fragments of the Msg were used, improving its
immunogenic power and consequently its application as an anti-
P. jirovecii antibody detection tool (Tomás et al., 2016). In the
present study, this RSA was used in combination with a new
RSA, produced based on the immunogenic behavior of P. jirovecii
Kex1 protein. This second RSA was also designed to hold more
than one reactive region of P. jirovecii Kex1 protein, in order to
increase the sensitivity and specificity of the serological approach.
The idea of using this new protein (Kex1), encoded by a single
copy gene (Kutty and Kovacs, 2003), emanate from the recent
reports that support its role in the protection of PcP (Gingo
et al., 2011; Kling and Norris, 2016) and to counteract the genetic
variation that the Msg protein may present during infection
(Hauser, 2019).
Both RSA were obtained with high purity (Figure 2C), and
were applied as antigenic tools in different ELISA assays (Table 1)
to assess whether specific anti-P. jirovecii antibodies can be
detected in human sera at the time of patient’s presentation
with symptomatology compatible with PcP. Thus, 76 serum
specimens collected at the time of patient’s BAL procedure for
PcP routine diagnosis were analyzed by these optimized indirect
ELISA with both RSA, for detection of IgG and IgM anti-
P. jirovecii antibodies. IgG ELISA results showed that, even
though IgG response is detected with both RSA, it is not possible
to distinguish patients with PcP from patients without P. jirovecii
infection by their IgG levels (Figure 3). That may be explained by
previous PcP events or by the reports of P. jirovecii colonization in
patients presenting diverse levels of immunodeficiency, primary
respiratory disorders, or even in the immunocompetent general
population (Wakefield et al., 2003; Medrano et al., 2005; Morris
and Norris, 2012), which could lead to the production of memory
cells that could induce IgG antibodies production throughout the
individual’s life.
Yet, IgM ELISA using each RSA as a coating antigen
(Figure 3), showed successful application in the serodiagnosis
of PcP, as anti-P. jirovecii levels detected, unlike IgG levels,
were significantly different between patients with and without
the disease (p ≤ 0.001). These results corroborate what had
previously been verified in studies with mice, where it was
suggested that the IgM isotype has a predominant role in
shaping the earliest steps in recognition and clearance of
P. jirovecii infection, since IgM-deficient mice showed to be
more susceptible to PcP progression (Rapaka et al., 2010). These
results suggest that IgM anti-P. jirovecii antibodies seems to
be a possible serological biomarker for active PcP diagnosis,
which could provide a major improvement over the current
diagnosis standards.
Taking this into consideration, the innovative character of the
present study stems from the use of these RSA in association
with gold nanoparticles with tunable bright colors, to design a
point-of-care platform for PcP diagnosis based on a solid-phase
(strip-based) test. The LFIA developed relies on the ability of
AuNPs to interact with the RSA to form conjugates that are
used as recognition tools capable of interacting with IgM anti-
P. jirovecii antibodies present in the serum of patients with PcP
Frontiers in Microbiology | www.frontiersin.org 13 December 2019 | Volume 10 | Article 2917
fmicb-10-02917 December 18, 2019 Time: 16:9 # 14
Tomás et al. Gold-Based Immunonanodiagnosis of Pneumocystis Pneumonia
FIGURE 7 | Comparative analysis of the results from LFIA strips containing AuNP-Msg-Casein conjugates (A,B) and AuNP-Kex1-Casein conjugates (C,D), after
applying the positive sample in different dilutions. (A,C) Digital pictures of LFIA strip results with sample dilutions ranging from 1:5 to 1:100 in Msg LFIA strips and
ranging from 1:5 to 1:40 in Kex1 strips. From bottom to top, strips were composed by the sample pad, the conjugate pad, the nitrocellulose membrane with the test
(T) and control (C) lines and the absorbent pad. (B) Quantification of color intensity of the control and test lines, where the intensity shown in each line corresponds to
the maximum height of the Gaussian line fitted by eReuss software.
(Figure 1). Although the traditional LFIA schemes for antibody
detection uses AuNPs conjugated with an immunoglobulin-
binding protein and the pathogen’s antigen immobilized in the
analytical zone (test line), some studies have shown that a
less conventional scheme using AuNPs directly conjugated with
pathogen’s antigen molecules for detection of serum antibodies
can achieve greater diagnostic sensitivity (Sotnikov et al., 2015,
2018). This increase in sensitivity is achieved by targeting the
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FIGURE 8 | Comparative analysis of the results from LFIA strips containing AuNP-Msg-Casein conjugates (A,B) and AuNP-Kex1-Casein conjugates (C,D), after
elution of a positive (+) or a negative (-) sample. (A,C) Digital pictures of LFIA strip results. From bottom to top, strips were composed by the sample pad, the
conjugate pad, the nitrocellulose membrane with the test (T) and control (C) lines and the absorbent pad. (B,D) Quantification of color intensity of the control and test
lines present in all replicates, where the intensity shown in each line corresponds to the maximum height of the Gaussian line fitted by eReuss software and the error
bars represent the standard deviation values.
capture of the antibodies of interest in the conjugation process,
due to the specific interaction of those antibodies with the
corresponding antigens present in the conjugates. Thus, as in
this study we sought to detect IgM, a class of immunoglobulins
whose serum levels remain elevated for a short period of time
during infection, less conventional AuNP-antigen conjugates
were chosen for LFIA development. Additionally, ELISA results
have shown that both Msg and Kex1 RSA are able to interact
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specifically with anti-P. jirovecii IgM antibodies in patient’s
sera samples. Then, two LFIA strips for the detection of anti-
P. jirovecii antibodies in human sera were developed, based on
AuNP-Msg and AuNP-Kex1 conjugates.
Lateral flow technology is well suited to point-of-care
diagnostics because it is robust and inexpensive, not requiring
power, a cold chain for storage and transport, or specialized
reagents (O’Farrel, 2013). This is possible because all necessary
materials and reagents are prepared to be stable and ready to use
at the time of sample application and the use of AuNPs ensures
a visual interpretation of the results, without the need for any
detection instrument.
Therefore, in this study, we synthetized MUA-capped AuNPs
with a large diameter (≈40 nm, see Supplementary Figure S9)
to obtain higher color intensity in the test/control lines with
lower AuNPs concentrations (Haiss et al., 2007; Santra et al.,
2017), which also helps to guarantee the low cost of the test.
Additionally, the 11-MUA ligand is known to favor electrostatic
protein conjugation with AuNPs (Gomes et al., 2012), which
helped AuNPs conjugation with the P. jirovecii’s RSA and the
formation of AuNP-Msg and AuNP-Kex1 conjugates.
These AuNP-RSA conjugates were characterized and
optimized through AGE assays which allow the separation of
the conjugates according to their differences in size and surface
charge (Guirgis et al., 2012; Franco and Pereira, 2013; Cavadas
et al., 2016; Kim et al., 2016; Almeida et al., 2018). Analysis of
AuNP-RSA conjugates with increasing RSA:AuNP molar ratios
after electrophoresis (Figures 4A,C) showed that as more RSA is
adsorbed at the AuNPs surface, the formed conjugate migrates
less in the agarose gel. This is consistent with increases in size,
which decreases their electrophoretic mobility, and decreases in
negative charge due to shielding induced by RSA coverage of the
AuNPs, decreasing their ability to migrate toward the positive
electrode. It was possible to define a plateau for the mobility
of the AuNP-RSA conjugates (Figures 4B,D), considering the
standard deviation values, that corresponds to saturation of the
AuNPs surface with the RSA. So, these assays confirmed the
formation of a persistent RSA corona around the AuNPs and
allowed the selection of an optimal molar ratio of ca. 3000 RSA
per AuNP for coverage of AuNPs with both RSA.
The ability of AuNP-RSA conjugates to interact with specific
anti-P. jirovecii antibodies from human sera was also evaluated
by AGE. The purpose of these assays was to establish a proof-of-
concept for the LFIA test, demonstrating that these conjugates
are indeed capable of functioning as anti-P. jrovecii antibody
recognition tools. To achieve this goal, AuNP-RSA conjugates
were incubated with human serum before and after treatment
with BSA and casein (see Supplementary Figure S14), which
are two non-antibody-reactive blocking agents that are usually
applied as immunoassay blockers (Binder and Isler, 2013). This
step was performed to ensure blockage of non-specific binding
sites available on the surface of AuNPs after saturation with the
RSA, so that non-specific interactions between AuNPs and serum
proteins were minimized. For both AuNP-RSA conjugates, casein
proved to be the most effective blocking agent, reducing non-
specific interactions between human sera and those conjugates
(see Supplementary Figure S14). However, even in the presence
of a pre-blocking step with casein, there is some residual
interaction between the negative serum and the conjugates
(Figure 5). This event can be due to the presence of IgG
anti-P. jirovecii antibodies in sera of patients with previous
contact with P. jirovecii, which is supported by reports of high
seropositivity for P. jirovecii in healthy individuals (Morris and
Norris, 2012). Yet, the presence of these type of interactions
does not impair the LFIA concept to be developed for two
main reasons. The first one is based on the fact that these
interactions will not be detected in the LFIA strip test because
the search is directed to the presence of IgM anti-P. jirovecii
antibodies, as this Ig class was the only one showing applicability
in distinction of patients with active disease from not infected
patients, with the ELISA results. The second reason is the
consistent presence of a migration shift in the AGE assay
resulting from different electrophoretic mobility’s of AuNP-
RSA-Casein conjugates after interaction with the positive and
negative samples (Figure 5). These shifts result from specific
interactions between anti-P. jirovecii antibodies present in the
sera of PcP patients and the RSA, which leads to a decrease
in the migration of the AuNP-RSA-Casein conjugates after
contact with the positive sample, functioning as a proof-of-
concept for the LFIA to be developed. It’s important to notice
that a more significant shift was achieved when using the
Kex1 RSA. Although this was theoretically unexpected, since
Kex1, unlike Msg, is not a specific or multicopy P. jirovecii
surface antigen, it was consistent with our ELISA results
that showed more significant differences between PcP and no
PcP patient’s IgM levels with the Kex1 RSA than with the
Msg RSA. Together, these results suggest that this antigen
will provide better diagnostic performance to the LFIA test
than the Msg RSA.
Even so, the next step was the assembly of the two LFIA strips
for detection of IgM anti-P. jirovecii antibodies in human sera.
For that, components from a commercial starter kit were tested.
Based on the visual interpretation of the strip results and on the
manufacturer’s recommendations for the development of LFIA
with AuNP conjugates, the final components were selected. Then,
the LFIA results were optimized to meet the following criteria:
the appearance of color in the test and control lines within a
reasonably short time (up to 10 min); presentation of a positive
and negative result easily distinguished by the naked eye and
confirmed by color quantification; minimum consumption of
reagents for cost control. Taking this into consideration, pre-
treatment steps were performed in the selected conjugate and
sample pads. During the optimization process, it was noted
that after adsorption, it was difficult to elute the AuNP-RSA-
Casein conjugates from the conjugate pad (data not shown).
Thus, as previously described by other authors that developed
colloidal gold-based lateral-flow immunoassays (Kolosova et al.,
2007; Li et al., 2015), we pre-treated the conjugate pad with
a buffer containing 5% sucrose, 1% BSA and 0.5% Tween
20, to improve conjugates stability and re-solubilization. On
the other hand, since the LFIA assay is only intended for
the detection of IgM class antibodies and since AGE assays
have shown that other immunoglobulins (probably IgG) can
interact with our conjugates, we considered adding a preliminary
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step to eliminate some of the patient’s IgG antibodies before
serum contact with the conjugates. For this purpose, a pre-
treatment of the sample pad with anti-human IgG antibodies
was made, as suggested by other authors which developed
LFIA for detection of IgM antibodies (Li et al., 2015). The
aim of this step was to increase the sensitivity of the test by
decreasing the percentage of anti-P. jirovecii IgG antibodies
that reach the conjugate pad, in order for the conjugates
to be more available to interact with the target IgM anti-
P. jirovecii antibodies.
The results from Figures 6A,C show that visually the test
and control lines became easier to see with the naked eye
and the results from Figures 6B,D confirmed this by color
quantification. The comparative analysis of color intensity
between strips before and after treatment, showed that the
color intensity of both control and test lines has increased after
treatment and that the software was not able to recognize the
visible signal on the test line before treatment with the cut-
off established. These results confirm that the pre-treatment
steps improve the interpretation of the results, demonstrating
that these steps are crucial to increase the assay sensitivity.
On the other hand, the results showed a more intense color
in the control line than in the test line. However, as the
signal in the control line is suffering from drying effect
(“coffee-ring”), we decided to make the following optimizations
dispensing the control and test antibodies in a line instead of
in a circle.
After, the sample dilution was also optimized (Figure 7). The
intensity of the signals in the control and test lines increased
with the dilution of the sample up to 1:50 in LFIA with the
AuNP-Msg conjugates and up to 1:20 in LFIA with the AuNP-
Kex1conjugates. Although signal weakening at higher dilutions
was expected due to excessive sample dilution, the lack of test
signals or the presence of a weaker signal at low dilutions,
with both AuNP-RSA-Casein conjugates, was not expected. This
is especially relevant for AuNP-Msg-Casein conjugates. We
speculate that excessive levels of anti-P. jirovecii antibodies in
the samples might lead to the formation of conjugate-antibody
aggregates, preventing their free movement along the elution
profile. The need for higher dilutions for conjugates with the
Msg RSA than for conjugates with the Kex1 RSA was anticipated
and consistent with our ELISA results, which demonstrated
that serum levels of anti-Msg antibodies are higher than serum
levels of anti-Kex1 antibodies. Taken together, these results
demonstrate that sample dilution and sample pad pre-treatment
are key factors that influence LFIA performance, and should be
reevaluated when validating these LFIA in a large cohort study,
before their implementation in the clinical practice.
Finally, triplicates of the optimized LFIA strips (see
Supplementary Figure S15) were tested with a pool of
serum specimens from patients with PcP (positive sample) and
a pool of serum specimens from patients without P. jirovecii
infection (negative sample) in the selected dilutions (Figure 8).
During these assays, it was established that 3 min are enough
for the sample to elute completely until the absorbing pad,
giving a LFIA final result. The digital pictures (Figures 8A,C)
and the color intensity analysis (Figures 8B,D) of the final
results showed that in strips tested with the negative pool,
only a colored line was visible on the control zone and
detected by the color quantification software in all replicates.
Additionally, in strips tested with the positive sample, a colored
line was visible and detected by the software in both test and
control zones as expected in all replicates, in both Msg and
Kex1 LFIA strips.
However, these results also show that further optimization
processes are needed. On the one hand, the variability between
the assays (represented by the error bars in Figure 8), which
may be justified by the lack of standardization of reagent
application and strips assembly, should be minimized through
automatic manufacturing processes. On the other hand, the
results show that the color intensity in the control line is
higher in strips tested with negative samples than in strips
tested with positive samples. Although this could be explained
by a higher number of free AuNP-RSA-Casein conjugates in
strips tested with negative samples, it should be addressed
in further optimizations by improving the conjugates:control
antibodies ratio used. Finally, the results from Msg LFIA
strips, showed that the conjugates seem to have formed
aggregates. Although this did not impair the performance of
the test, future optimization should focus on maintaining the
stability of these conjugates after adsorption to the conjugate
matrix, in order to obtain equally intense red lines in
the LFIA strips.
CONCLUSION
In conclusion, this study provides a proof-of-concept that a
point of care diagnostic test for PcP can be developed and that
both LFIA developed allow the detection of IgM anti-P. jirovecii
reactive against both RSA. This is important because in our
previous study (Tomás et al., 2016) and in this study, we verified
that IgM levels could be used as a serological biomarker of
P. jirovecii active infection. However, future work is needed
in order to optimize and validate this diagnostic approach in
a large prospective study with patients from different clinical
groups, in order to assess the sensitivity, specificity and accuracy
of the two LFIA strips proposed, individually and combined.
Only with these results, it will be possible to confirm the
need to study the reactivity against more than one RSA in
parallel and then optimize a diagnostic kit, for implementation
in the clinical practice. If both AuNP-RSA conjugates prove
useful in PcP diagnosis, a multiplex strategy, based in the
use of two conjugate pads for the simultaneous detection of
two proteins (Zhu et al., 2013), could be adapted for the
present LFIA strips.
The technology proposed in this study reveals to the scientific
community how these less conventional conjugates can be used in
the development of an alternative approach to the conventional
diagnosis of PcP, reducing the need for the current invasive
procedures used in the collection of respiratory specimens, as
well as reducing time response and costs associated with PcP
diagnosis. Ultimately, this study will help in the management of
PcP in industrialized countries, also having a major impact on
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developing countries with low income and lack of technology,
where PcP is an emerging disease with high prevalence and
poorly controlled.
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